Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Motacabtagene Lurevgedleucel · CTX120

Cell therapy (CAR-T) · Kills target cells, directed at B-cell maturation antigen (TNFRSF17) · developed by CRISPR Therapeutics

Phase 1 Most advanced trial (none active)
CRSP Developer
1 Registered trials

What is Motacabtagene Lurevgedleucel?

Motacabtagene lurevgedleucel is an allogeneic T-lymphocyte cell therapy gene-edited with CRISPR-Cas9 to disrupt endogenous TCR and MHC class I expression and to express a chimeric antigen receptor targeting BCMA. It binds BCMA-overexpressing cells and kills them through cytotoxic T-lymphocyte activity. It is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CTX120
Drug type
Cell therapy (CAR-T)
Targets
B-cell maturation antigen (TNFRSF17) (antigen)
Mechanism
Kills target cells, directed at B-cell maturation antigen (TNFRSF17)
Therapy area
Oncology
Developer
CRISPR Therapeutics AG (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04244656 Phase 1 Multiple Myeloma Terminated CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Other drugs acting on TNFRSF17

More from CRISPR Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind Motacabtagene Lurevgedleucel

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.